Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Gynecologic Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
J Surg Oncol. 2024 Jan;129(1):120-125. doi: 10.1002/jso.27552.
The molecular subtypes of endometrial carcinoma (EC) were first described by The Cancer Genome Atlas (TCGA) a decade ago. Using surrogate approaches, the molecular classification has been demonstrated to be prognostic across EC patients and to have predictive implications. Starting in 2020, the molecular classification has been incorporated into multiple guidelines as part of the risk assessment and most recently into the International Federation of Gynecology and Obstetrics (FIGO) staging. This review article discusses the implementation of the EC molecular classification into clinical practice, the therapeutic implications, and the molecular and clinical heterogeneity of the EC molecular subtypes.
十年前，癌症基因组图谱（TCGA）首次描述了子宫内膜癌（EC）的分子亚型。通过替代方法，已经证明分子分类对 EC 患者具有预后意义，并具有预测意义。从 2020 年开始，分子分类已被纳入多个指南，作为风险评估的一部分，最近又被纳入国际妇产科联合会（FIGO）分期。本文讨论了将 EC 分子分类应用于临床实践、治疗意义以及 EC 分子亚型的分子和临床异质性。
